Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Shire licenses Amigal, Plicera and AT-2220 from Amicus for markets outside of the U.S.

Nov. 14, 2007

Biopure responds to U.K. commission on human medicines' review of Hemopure

Nov. 13, 2007

BioGeneriX and Neose report positive data from two phase I trials of GlycoPEG-GCSF

Nov. 13, 2007

Recent patents describe novel antidiabetic agents

Nov. 13, 2007

Novel therapeutic agents for genetic disorders reported in recent Technion patent

Nov. 13, 2007

Weight loss synergy seen with bupropion/naltrexone in obesity study

Nov. 13, 2007

GTx and Merck & Co. enter agreement to develop selective androgen receptor modulators

Nov. 12, 2007

Results from a clinical study and safety update presented for Novartis's Galvus

Nov. 12, 2007

Qnexa improves quality of life in obese subjects

Nov. 12, 2007

First identified mutation in the sarcosine dehydrogenase gene may be associated with sarcosinemia

Nov. 12, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...